Table 1 Baseline Characteristics

From: Administrative-driven hierarchical management of atrial fibrillation on cardiovascular events: a prospective matched cohort study

 

Total (n = 8730)

ADHM cohort (n = 1455)

UC cohort (n = 7275)

P value

Female sex (n, %)

4008 (45.9)

668 (45.9)

3340 (45.9)

1.000

Age (years)

76.0 ± 9.9

76.0 ± 9.5

76.0 ± 9.9

0.848

CHA2DS2-VASc

4.96 ± 1.93

4.96 ± 1.96

4.96 ± 1.93

0.970

HAS-BLED

2.66 ± 0.98

2.67 ± 0.99

2.66 ± 0.98

0.201

Hypertension (n, %)

8103 (92.8)

1339 (92.0)

6764 (93.0)

0.201

Diabetes (n, %)

4758 (54.5)

795 (54.6)

3963 (54.5)

0.908

Stroke/TIA (n, %)

4476 (51.3)

748 (51.4)

3728 (51.2)

0.590

Systemic embolism (n, %)

300 (3.4)

57 (3.9)

243 (3.3)

0.270

Heart failure (n, %)

4584 (52.5)

757 (52.0)

3827 (52.6)

0.687

Peripheral artery disease (n, %)

307 (3.5)

62 (4.3)

245 (3.4)

0.091

Myocardial infarction (n, %)

268 (3.1)

49 (3.4)

219 (3.0)

0.471

Valvular heart disease (n, %)

288 (3.3)

51 (3.5)

237 (3.3)

0.630

COPD (n, %)

1940 (22.2)

327 (22.5)

1613 (22.2)

0.800

OSAHS (n, %)

69 (0.8)

16 (1.1)

53 (0.7)

0.144

History of major bleeding (n, %)

971 (11.1)

173 (11.9)

798 (11.0)

0.308

History of cancer (n, %)

1083 (12.4)

179 (12.3)

904 (12.4)

0.896

Renal deficiency (n, %)

444 (5.1)

83 (5.7)

361 (5.0)

0.239

Liver deficiency (n, %)

1404 (16.1)

231 (15.9)

1173 (16.1)

0.815

Medication history

 Regular anticoagulation*

3531 (40.4)

590 (40.5)

2941 (40.4)

0.930

 Warfarin (n, %)

941 (10.8)

156 (10.7)

785 (10.8)

0.938

 Dabigatran (n, %)

902 (10.3)

160 (11.0)

742 (10.2)

0.362

 Xa factor inhibitor (n, %)

2250 (25.8)

394 (27.1)

1856 (25.5)

0.212

 Antiplatelet drug (n, %)

2935 (33.6)

472 (32.4)

2463 (33.9)

0.297

 Antiarrhythmic drugs (n, %)

2876 (32.9)

480 (33.0)

2396 (32.9)

0.968

 Rate control drugs (n, %)

3320 (38.0)

576 (39.6)

2744 (37.7)

0.180

 Statin (n, %)

2429 (27.8)

397 (27.3)

2032 (27.9)

0.616

 ACEi/ARB/ARNi (n, %)

3902 (44.7)

650 (44.7)

3252 (44.7)

0.985

 MRA (n, %)

968 (11.1)

167 (11.5)

801 (11.0)

0.604

 SGLT2i (n, %)

671 (7.7)

108 (7.4)

563 (7.7)

0.679

History of cardiac procedures

 Catheter ablation (n, %)

957 (11.0)

162 (11.1)

795 (10.9)

0.818

 LAAC (n, %)

107 (1.2)

18 (1.2)

89 (1.2)

0.965

 Cardioversion (n, %)

73 (0.8)

14 (1.0)

59 (0.8)

0.563

  1. ACEi angiotensin-converting enzyme inhibitor, ADHM administrative-driven hierarchical management, ARB angiotensin II receptor blocker, ARNi angiotensin receptor-neprilysin inhibitor, CHA2DS2-VASc congestive heart failure, hypertension, age 75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65–74, female, COPD chronic obstructive pulmonary disease; HAS-BLED hypertension, abnormal renal and/or liver function, previous stroke, bleeding history or predisposition, labile international normalized ratios, elderly, and concomitant drugs and/or alcohol excess; LAAC= left atrial appendage closure; MRA= mineralocorticoid receptor antagonist, OSAHS obstructive sleep apnea-hypopnea syndrome, SGLT2i sodium-glucose co-transporter 2 inhibitor, TIA transient ischemic attack, UC usual care. * Regular anticoagulation indicates patients had at least three prescriptions of oral anticoagulants within 12 months before enrollment. The independent Student’s t-tests and the χ2 tests were adopted for continuous and categorical variables, respectively. Two-sided P value was adopted. Source data are provided as a Source Data file.
Back to article page